BeiGene Ltd Stock News

The threat of a forced delisting is weighing heavily on these two Chinese biotech stocks.

The threat of a forced delisting is weighing heavily on these two Chinese biotech stocks.

BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces authorisation of BRUKINSA (zanubrutinib) for the treatment of adults with Waldenströms macroglobulinemia in Great Britain.

The declines come after the Financial Times reported that the U.S. Commerce Department on Thursday is expected to place some Chinese companies involved in biotechnology on its entity list, which is de

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that it has completed its previously announced initial public offering (STAR Offering) on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange (SSE). The shares offered in the

Chinese biotech company BeiGene Ltd opened lower on its Shanghai debut on Wednesday after raising over $3 billion in the biggest STAR Market listing this year.

Zacks Investment Research lowered shares of BeiGene (NASDAQ:BGNE) from a buy rating to a hold rating in a research report report published on Monday morning, Zacks.com reports. According to Zacks, BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The companys clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is []

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody

BeiGene (NASDAQ:BGNE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Monday, Zacks.com reports. According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana […]

The U.S.-listed Chinese stocks with the most American ownership don't include many of the big names familiar to Wall Street, according to Morgan Stanley.

BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced results from a planned interim analysis of the Phase 3 SEQUOIA trial in patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL), including the randomized Cohort

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene presents updated safety and efficacy findings on BRUKINSA (zanubrutinib) in patients with B-Cell Malignancies intolerant to BTK inhibitors.

The global Merkel Cell Carcinoma Treatment market size is projected a CAGR of 7.8% during 2021-2027. The rise in the number of cases of merkel cell carcinoma around the world has influenced the demand for novel medications for merkel cell